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1. INTRODUCTION 
1.1 Kidney transplantation 
Since the first unsuccessful attempt in 1933 (1;2), kidney transplantation has progressed 
from being an experimental investigation to a safe and more or less routine clinical 
procedure. The first kidney transplantation to achieve a successful, long-term outcome was 
undertaken in Boston in 1954 by a team led by Dr. Joseph E Murray (3;4). A kidney was 
transplanted between two identical twins. Kidney function was restored and the recipient 
survived with good kidney function until suffering cardiac death eight years later. The donor 
suffered no serious side effects. Clearly, this success was of limited practical value since 
identical twins are rare. For his pioneer work with transplantation, Murray was awarded the 
Nobel Prize for medicine in 1990. 
The success of the transplantation in 1954 inspired pioneering groups in Boston and Paris to 
perform unrelated transplantations using total body irradiation and corticosteroids as 
immunosuppression (5;6). This non-specific mode of immunosuppression was, however, 
both cumbersome and associated with serious side effects and unacceptable mortality rates 
from infections. In 1961, azathioprine (AZA) was introduced as an immunosuppressant for 
use in human organ transplantation (7;8). The immunosuppressive effect of AZA was 
reversible and could be achieved with a relatively low incidence of side effects. It now 
became possible to perform transplantations between individuals who were not genetically 
identical. Consequently, kidney transplantation became a viable treatment for selected 
patients with end stage renal disease (ESRD). At that time, graft survival at one year using 
AZA and steroids was approximately 50% (9). 
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Increased knowledge of the immunological mechanisms responsible for the development of 
rejection, and eventually the introduction of cyclosporine A (CsA) in 1982, resulted in 
further improvements in graft survival following kidney transplantation (10). Since then, 
new and more potent immunosuppressive drugs such as mycophenolate mofetil (MMF) and 
the interleukin 2 receptor (IL-2R) antagonists have been developed. The use of these drugs 
has led to even further reductions in acute rejection rates (11). These advances have made it 
possible to start large scale transplantation programmes and today kidney transplantation is 
the preferred treatment option in patients with ESRD eligible for the surgical procedure 
(12). 
In Scandinavia, the first kidney transplantation was attempted at Rikshospitalet in Oslo, 
Norway in 1956. The first transplantation in Scandinavia to achieve a successful long-term 
outcome, however, was performed at Ullevål hospital in 1963. The recipient survived for 22 
years before dying from a ruptured aortic aneurysm (13). Since 1983, as part of a national 
policy, all solid organ transplantations in Norway have been performed at Rikshospitalet. 
The number of kidney transplantations conducted at Rikshospitalet has steadily increased 
and now totals between 250 and 300 procedures per year. 
 
1.2 Ageing population 
The average age of the Norwegian population has increased markedly over the last three 
decades. The number of Norwegians aged 70 years or older has increased from 320,000 (8% 
of the total population) in 1970 to more than 500,000 (11% of the total population) in 2008. 
Based on a conservative estimate, this figure is likely to rise to approximately 840,000 (14% 
of the total population) by 2030 (14). 
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Figure 1. The Norwegian population over 70 years of age; past, present and future. Data extracted from 
www.ssb.no November 2008. 
 
Similar demographic changes are taking place across most of the western world. In the 
European Union, it is estimated that the proportion of people older than 65 will increase 
from 16.7% in 2005 to 28.4% by 2050 (15). Similarly, in the United States, the proportion 
of people older than 65 is expected to increase from 12.4% in 2005 to 21.6% by 2050 (16). 
The increase in the elderly population has consequently led to a rise in morbidity rates. 
 
1.3 Epidemiology and treatment options for elderly ESRD patients 
Common risk factors for chronic kidney disease (CKD) include hypertension, 
cardiovascular disease (CVD), diabetes mellitus (DM), family history of CKD, and older 
age. The National Health and Nutrition Examination Survey (NHANES) is a series of health 
examination surveys, begun in 1960, designed to monitor the health and nutritional status of 
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the non-institutionalized, general population in the United States. The most recent survey 
was conducted between 1999 and 2004 and included 14,632 people aged 20 years (17). 
Data from this NHANES showed that the risk of CKD in people aged over 60 was much 
higher (odds ratio 5.89), compared with those aged between 20 and 39 (18). Data from the 
Norwegian Renal Registry in 2008 showed that vascular/hypertensive disease was the 
number one underlying cause of CKD and accounted for 27% of all new patients starting 
renal replacement therapy (RRT) (19). In patients older than 70 starting RRT, this figure 
rises to 46% (personal information – Torbjørn Leivestad October 2009). 
CKD is staged according to severity from stage 1 to stage 5. RRT is usually not started 
before the patient has reached stage 5. Many elderly patients with stage 4 CKD have slowly 
declining kidney function and die before reaching stage 5 (20). Despite this, elderly patients 
have been the fastest growing ‘population’ requiring RRT both in Europe and in the United 
States (21-25). In 1980, the median age of patients starting RRT in Norway was 53 years. 
This had increased to 65 years in 2008 (19). 
 
Figure 2. Age of new patients at start of RRT in Norway 1990 - 2008. Data retrieved from the 
Norwegian Renal Registry. Reprinted with permission from Torbjørn Leivestad. 
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As shown in Figure 2, the median age of patients starting RRT has stabilised during the last 
decade. Similar trends are observed in other countries (18;26). It is possible that the efforts 
made to prevent the development of ESRD, especially among patients with hypertension, 
have led to this stabilization. On the other hand, the absolute number of elderly patients in 
need of RRT will still increase substantially owing to the ageing populations described in 
section 1.2. 
Patients with advanced CKD have different options for active treatment: 
1. Dialysis, either as haemodialysis (HD) or peritoneal dialysis (PD). 
2. Preemptive kidney transplantation. 
3. Kidney transplantation after the start of dialysis. 
Traditionally, elderly patients with advanced CKD have been selected for dialysis treatment, 
with only a small minority being considered for kidney transplantation. Elderly patients with 
severe comorbidity may be found unfit for active treatment although this may not lead to 
any shortening of their life expectancy (27). In some cases it is extremely difficult to decide 
whether a patient will tolerate, and thereby benefit from, dialysis treatment. Most elderly 
patients with advanced CKD develop symptoms that may either be suggestive of uraemia, 
or simply be a consequence of advanced age and/or comorbidity. In such cases it is 
sometimes necessary to start acute dialysis treatment in order to save the patient’s life, and 
then decide subsequently if the treatment should be permanent or not. An important factor in 
this process is how long the patient is expected to survive, with or without active treatment. 
A recent report describing the outcome of 8,977 chronic dialysis patients showed that the 
mortality rate in patients with ESRD had not changed over the last 12 years, despite a 
significant increase in the age of the dialysis population (28). The authors’ hypothesis is that 
selected patients benefit from the improvements in dialysis technology, uraemia 
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management, and treatment of dialysis-related complications. Interestingly, in patients aged 
over 74, the mortality rate significantly decreased during the 12 year observation period. 
Several strategies have been developed to predict early and long-term prognoses in CKD 
(29-31), and these may be used to help select patients eligible for RRT. 
Kidney transplantation is generally regarded as the best treatment option for patients with 
ESRD (12;32-35). Previous studies indicate that selected elderly patients, despite having a 
limited life expectancy, often benefit from kidney transplantation (36-39). Consequently, the 
proportion of elderly patients on transplant waiting lists has increased during the last years. 
In 2008 in the United States, more than 15% of patients on transplant waiting lists were 
aged over 65 (40), compared with only 7% in 1997 (25). Similarly, in Europe, the 
proportion of kidney transplant recipients over the age of 65 has increased from 3.6% in 
1991 to 19.7% in 2007 (41). The majority of previous reports concerning transplantation in 
‘elderly patients’ have generally involved patients aged between 60 and 70 (36;42-46). 
There are few reports describing kidney transplantation outcomes in patients above 70 years 
old, and the most important of these publications are based on registry data from multiple 
centres reflecting various transplant protocols (24;38). Compared with age-matched dialysis 
patients, previous studies have indicated that survival and quality of life is favorable after 
transplantation even in recipients aged 65 - 70 (36;38;47-49).  
 
1.4 Selection of elderly patients for kidney transplantation 
The increasing number of elderly patients with ESRD presents great challenges for 
physicians. One such challenge is how to select which elderly patients with ESRD whom 
are most likely to benefit from kidney transplantation. Traditionally, a standard comorbidity 
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screening and treatment algorithm has been employed, independent of patient age. Patients 
with less comorbidity tend to be accepted for transplantation, while those with greater 
comorbidity receive life-long dialysis treatment. 
In general, the degree of comorbidity, in particular diabetic nephropathy and cardiovascular 
disease, at the time of transplantation, has a deleterious effect both on recipient and allograft 
survival (50;51). There is, however, limited information available relating to the effects of 
comorbidity in kidney transplant recipients at an advanced age. Several scoring systems 
have been proposed to assess the burden of comorbidity at the time of kidney 
transplantation. The Charlson comorbidity index (CCI) has been validated as the best 
predictive tool for measuring comorbidity in this setting (52). The CCI score ranges from 0 
(no comorbidity) to 24 (maximum comorbidity). The lowest possible CCI score at the time 
of kidney transplantation is 2 (the presence of pre-transplant kidney failure). The CCI score 
has been validated in patients older than 60 years (53), but it has not previously been 
evaluated as a prognostic index for mortality or graft loss in recipients older than 70 years. 
 
1.5 Donor organ pool and allocation strategies 
A major concern in kidney transplantation is the lack of organs.  In general, there are far 
more patients on waiting lists than there are available organs. By March 31st 2008, 6,784 
patients were waitlisted for a kidney transplant in the UK, whereas only 1,437 deceased 
donor and 829 living donor transplantations were performed the previous year (54). This 
inevitably means increased waiting times, and patients dying while on waiting lists. By the 
end of 2008, 10,687 patients were registered on the Eurotransplant kidney waiting list (55). 
Among these, 52% had been on the waiting list for more than two years, and 75% had been 
 15
 
                                                                                                                     
on dialysis for more than two years. It would be difficult, even unethical, to expand the 
number of patients eligible for kidney transplantation, without simultaneously expanding the 
number of organs available. Strategies for expanding the overall donor pool include 
increased use of living donors (56-60), donation after cardiac death programs (61-65), 
altruistic living donation (66), introduction of standardized donor management protocols 
(67) and increased use of expanded criteria donors (ECD) (68-70). ECDs are defined as all 
deceased donors older than 60 years, and those aged 50 to 59 with at least two of three 
medical criteria: hypertension, cerebrovascular cause of death or serum creatinine level 
above 132.6 μmol/L (1.5 mg/dL) (56;71-73). An important issue in the allocation process is 
to match the suspected life of the transplant to the suspected life of the recipient. By 
avoiding giving young kidneys to elderly recipients it is possible to increase the overall graft 
life and thereby utilize the graft source as optimal as possible (74). Recently, a kidney donor 
risk index (KDRI) has been developed for estimating the risk of graft failure after 
transplantation (75). The Eurotransplant Senior Program (ESP) was launched in 1999 as an 
alternative old-for-old organ allocation system (76), and in the United States, a new 
allocation system named Life Years From Transplant (LYFT) is being considered (77). 
 
1.6 The Norwegian experience with elderly kidney transplant recipients 
The Norwegian kidney transplantation waiting list has, up to now, been kept relatively 
constant at below 50 per million inhabitants. This can be explained by a relative low 
incidence of ESRD (78) and an active living donor transplant programme (58;79),  Patients 
have been accepted for kidney transplantation using a standard screening algorithm without 
a formal upper age limit. More than 20 years ago it was reported from our centre that 
transplantation was feasible even in selected patients beyond 70 years of age (80).  Living 
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donations are also accepted, and in particular spousal donors are becoming increasingly 
common in this age group. Because we have one large transplant centre serving 
approximately 4.8 million inhabitants, and a liberal policy with kidney transplantation in 
elderly patients, we have, to our knowledge, the largest amount of data from a single centre 
describing kidney transplantation in the elderly. 
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2. AIMS OF THE STUDIES 
The rising number of patients with ESRD placed on transplant waiting lists has led to the re-
evaluation of selection criteria for transplantation, including in Norway. A common 
question is whether high age per se should be a contraindication for transplantation. 
Primarily we wanted to evaluate outcomes in kidney transplant recipients older than 70 
years and compare them with younger recipients, as well as identify clinical variables 
associated with good or poor outcome. We also wanted to compare outcomes of 
transplanted elderly patients with patients of the same age accepted for transplantation who 
had remained on dialysis while waiting for an appropriate organ. In addition, we also 
wanted to evaluate the use of older donors for older recipients. 
We aimed to answer the following key specific questions: 
1. Is kidney transplantation a safe and preferred treatment for elderly ESRD 
patients without an upper age limit? 
2. Are there any pre-transplant or early post-transplant modifiable clinical 
variables relevant to kidney transplantation outcomes in the elderly?  
3. Should kidneys from old deceased donors be discarded owing to their advanced 
age? 
4. Is kidney transplantation superior to dialysis in elderly patients with ESRD? 
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3. SUBJECTS AND METHODS 
3.1 Study design 
3.1.1 Papers I - II 
Survival data for all patients who received their first single kidney transplant at 
Rikshospitalet between 1990 and 2005 were retrieved from the Norwegian Renal Registry 
and analyzed as described in section 3.2.1. The patients were stratified according to their 
age at transplantation. The ‘elderly’ recipients, defined as those aged 70 years or older were 
compared with a group of ‘senior’ recipients aged 60 to 69 years old. These two groups 
were also compared with a control group consisting of ‘average’ adult kidney recipients at 
our centre (age 45-54 years). 
Baseline clinical characteristics of the recipients were retrieved from the registry and from 
the Rikshospitalet hospital records. Information about traditional risk factors, 
immunosuppressive treatment, complications and hospitalisations were also retrieved. 
Comorbidity at transplantation (paper II) was quantified retrospectively using the Charlson 
Comorbidity Index, as described by Jassal et al (52). The calculation was individually 
performed for each patient based on review of hospital records. 
 
3.1.2 Paper III 
Medical files including survival data of all deceased donors older than 75 years, from whom 
single kidneys had been transplanted into recipients aged over 50 years, between 1990 and 
2007, were retrieved and analysed. Data were retrieved from the same sources as for paper I 
and paper II. In addition, all graft biopsies obtained at transplantation and during the first 
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month post-transplantation were retrospectively analysed and scored by a blinded 
pathologist using both the Banff criteria (81) and the criteria defined by Remuzzi et al. (82). 
 
3.1.3 Paper IV 
Survival data for all patients starting dialysis in Norway between 1990 and 2005 were 
retrieved from the Norwegian Renal Registry. Patients accepted for transplantation and put 
on the transplantation waiting list were included in the study. Survival analyses using a 
time-dependant Cox model were performed in order to compare survival rates between 
transplanted patients and those remaining on the waiting list. In addition, clinical 
characteristics were retrieved from the registry and hospital records as described for the 
previous papers. 
 
3.2 Statistics 
A two-sided unpaired t-test or Mann-Whitney test was used, as appropriate, to compare 
groups. In paper I and II, the elderly recipient group was chosen as index for comparative 
analysis. Owing to the use of two tests to compare the index group versus the two other 
groups, Bonferroni correction was used and the level of significance for each test was set at 
0.025 to achieve an overall level of significance of 0.05. Fisher’s exact test was used to 
analyse binary data. We performed logistic regression analyses to identify risk factors for 
acute cellular rejection. 
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3.2.1 Survival analysis 
Survival data were assessed using the Kaplan-Meier method, uni-/multivariate Cox 
regression analysis, and a time-dependent Cox model (paper IV). The Kaplan-Meier curves 
were compared by the log rank test. The events defined as end points in the analyses were 
patient death (all papers), death-censored graft loss (papers I-III) and uncensored graft loss 
(papers I-III). Patient survival was defined as time from transplantation (all papers) or from 
waiting list/start of dialysis (waitlist group, paper IV) to patient death or censoring due to 
loss from follow up (emigration), end of study or transplantation (waitlist group, paper IV). 
Graft survival was defined as the time from transplantation to patient death, time to loss of 
graft function with need of dialysis, or to censoring as described for patient death. The graft 
survival was analyzed in two different models, with or without censoring for death with 
functioning graft. The analyses were implemented using SPSS 15.0. 
 
3.2.2 Kaplan-Meier method 
The Kaplan-Meier method is commonly used for estimation of survival probability (83;84). 
Survival is the time to a predefined event, for example death or graft loss used in the present 
studies. In addition to defining the event, it is also important to define a distinct starting 
point for survival. In randomised clinical trials (RCT), the survival time is usually measured 
from the time of randomisation. We chose the time of transplantation as baseline for 
survival analysis in papers I, II and III. In paper IV, the time of waitlisting or start of 
dialysis (latest for both) was used as the starting point for the waitlist group, whereas in the 
transplant group, it was set at the time of transplantation as in the previous papers. 
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A patient may be censored from the survival analysis if they are, for any reason except for 
the defined events, lost to follow up or no longer fulfil the inclusion criteria. The most 
typical example is a patient who has not experienced the event when the study is terminated. 
These patients will be censored owing to the end of study. In the case of graft survival, 
death with a functioning graft may be regarded as an event. On the other hand, however, it 
is not known how long the graft would have survived if the patient had not died. In this 
case, death with a functioning graft could also be censored, and not counted as an event. 
Patients who withdraw from the study, for example due to emigration or if a patient chooses 
to do so, can also be censored from the survival analysis. 
 
Figure 3. Survival of eight patients counted from date of inclusion in the study to reaching an event () 
or to censoring due to loss of follow up (patient 3) or end of study (patient 1, 6 and 7). The length of each 
patient’s line represents their event-free survival in the study. 
 
By using the Kaplan-Meier method, survival in the future can be estimated by analysing 
data from the past. The probability of survival is calculated for each point of time an event 
has taken place. For example, if the first event takes place at day 7, the probability of not 
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having an event during the first 6 days is 1.0. The cumulative probability of survival can be 
expressed: 




	 

n
yn0,1 , where n is the total number at risk and y is the number of events. 
If there are 10 patients at the start of the study (day 0), the probability of surviving day 7 
is: 9.0
10
1100.1 




	 
 . If the next event takes place at day 17, the probability of surviving the 
time period from day 7 throughout day 17 is: 89.0
9
19





	 
  and the cumulative survival 
probability from the start of study throughout day 17 is: 8.089.09.00.1  . If a patient is 
censored from the study between day 17 and day 33 when the next event takes place, this 
has to be taken into account when calculating the probability of survival during this interval. 
We know that 8 patients started this interval, one of them was censored, so only 7 survived 
until day 33 (n=7). In addition, one patient had an event at day 33 (y = 1) so 6 patients are 
left after day 33. The probability of survival from day 17 throughout day 33 
is: 86.0
7
17





	 
  and the cumulative probability of surviving day 33 is: 69.086.08.0  . By 
using these values for cumulative survival, we can construct a Kaplan-Meier plot illustrating 
how the survival decreases with time. 
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Figure 4. Cumulative survival illustrated with a Kaplan-Meier plot. 
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From the plot we can easily interpret the cumulative survival at different times. It is possible 
to compare the survival between two test groups by using the log rank test (85). The log 
rank test is principally a chi square test that compares the relationship between observed and 
expected values. H0 for the test is that there is no difference between the survival curves of 
the two groups. The test is convenient to use when the curves do not cross each other and 
when there are more than 10 subjects in each group. It is important to know that the log rank 
test is purely a test of significance. It cannot provide either an estimate of the size of the 
difference between the groups or a confidence interval. The log rank test is further described 
in statistical textbooks (86;87). 
 
3.2.3 Cox proportional hazard models 
A Cox proportional hazard model determines the relationship between hazard rates in 
different groups of the patient population. It is possible to compare the survival of different 
patient groups and account for confounding effects (88). In a comparison of two different 
treatment protocols, the hazard rate for the standard treatment is h0(t) and h1(t) for the new 
treatment. If it is assumed that the relationship between the two hazard rates is constant at 
any point of time during the whole treatment period, the hazard rates are proportional: 
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The complexity and usefulness of the model can be increased by introducing and adjusting 
for more variables. To avoid negative values of , it is convenient to define  as exp(). 
With several variables included in the model, the equation for  is:  = 1x1 + ····· + nxn, 
where x1, x2, ···, xn are values of a set of variables and 1, 2, ···, 3 are regression 
coefficients. The variables can be continuous e.g. age, time on dialysis, cold ischaemic time, 
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or discrete e.g. gender or treatment modality etc. The general proportional hazard model can 
be expressed as h(t) = h0(t)exp(1x1 + ····· + nxn ) where h0(t) is denoted as the ‘baseline 
hazard’. The baseline hazard is a value that describes the hazard before new variables are 
included in the model. With this model, it is important that the variables are constant during 
the entire trial. If not, a model with a time dependant variable has to be used. 
 
3.2.4 Time-dependant Cox model 
In certain settings, as for example when the survival curves of the Kaplan-Meier plot cross 
each other as a result of changing hazards by time, it is necessary to create a model with a 
time dependant variable, to evaluate whether survival rates in the groups we are comparing 
are different from each other. In this case there is a time-varying risk factor (89). In paper 
IV, we defined two risk factors: 1) being on the waiting list and 2) transplantation. As many 
patients fall within both the waitlist and the transplant groups, they have two different 
hazards that need to be compared. In our model, we defined waitlist and transplantation as 
the two values of the time dependant variables. In addition we introduced several other 
possible confounders into the model as described in the result section, to ensure that the 
final result was also adjusted for these variables. 
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4. RESULTS 
4.1 Paper I 
In this paper, patient and graft outcomes in 301 ‘elderly’ kidney transplant recipients ( 70 
years of age) were compared with 513 ‘senior’ recipients (60 – 69 years of age) and a 
‘control’ group comprising  512 ‘average’ adult kidney recipients (age 45-54 years). A 
living donor transplantation was performed in 35% of patients; 17% in elderly recipients, 
34% in senior recipients (P < 0.001) and 47% in control recipients (P < 0.001). Preemptive 
transplantation was performed in 19% of patients; 10% in elderly recipients, 18% in senior 
recipients (P = 0.003) and 25% in control recipients (P < 0.001). The elderly group had 
significantly lower rate of acute rejections during the first 12 weeks, compared with both the 
senior group (P = 0.005) and the control group (P = 0.002). Elderly and senior recipients 
had a higher incidence of death with a functioning graft during the follow-up: elderly 45%, 
senior 31% (P < 0.001), control 13% (P < 0.001). Five year patient survival was 56% in the 
elderly group, 72% in the senior group (P < 0.001) and 91% in the control group (P < 
0.001). Cardiovascular disease (34%) and infection (27 %) were the most frequent causes of 
death. Five year graft survival was 53%, 70% and 84% in the elderly, senior and control 
groups, respectively. There were however no difference in graft survival when censoring for 
death with functioning graft. Consequently, the inferior graft survival in the elderly, reflects 
a natural higher risk of death with functioning graft. 
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4.2 Paper II  
In this paper, potentially relevant clinical parameters for patient survival, graft survival and 
acute rejection were evaluated in ‘elderly’ (n = 354), ‘senior’ (n = 577) and ‘control’ (n = 
563) recipients. Acute rejection during the first 90 days (HR 1.74 [1.34-2.25], P < 0.001), 
time on dialysis before transplantation (HR 1.02 per month [1.01-1.03], P < 0.001), and 
donor age  60 years (HR 1.52 [1.14-2.01], P = 0.004) were all associated with increased 
mortality in the elderly. Although comorbidity determined by the CCI score was not 
associated with increased mortality in the elderly group (HR 1.05 [0.98-1.12]), an 
association was found both in the senior (HR 1.17 per unit increase of the CCI score [1.08-
1.27], P < 0.001), and control groups (HR 1.33 [1.19-1.48], P < 0.001). Delayed graft 
function (HR 3.69 [2.01-6.79], P < 0.001), donor age  60 years (HR 2.42 [1.30-4.49], P = 
0.005) and presence of human leukocyte antigen (HLA) antibodies (HR 3.96 [1.38-11.37], P 
= 0.011) were independently associated with death-censored graft loss in the elderly. 
Treatment with AZA rather than MMF, any HLA-A or HLA-DR mismatch, donor age  60 
years, and presence of HLA antibodies were associated with increased risk for early acute 
rejections (the first 90 days post- transplant) in all age groups. 
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4.3 Paper III  
In this paper we investigated whether using kidneys from deceased donors with advanced 
age (older than 75 years) may be a way to increase the donor pool available for elderly 
patients with ESRD. Data from 54 single kidney transplantations using organs from 29 
donors older than 75 (median 77.5, range 75.2-86.1) were assessed. Mean recipient age was 
70.1 (range 50.6-82.4). 52 grafts (96%) had post-transplant function. Death-censored graft 
survival rates at 1, 3 and 5 years were 87%, 83% and 83%, respectively. Patient survival 
was 81%, 75% and 59% at the same time points. At follow up after a mean of 23 months 
(range 6-144 months), 35 recipients were alive with median serum creatinine level 163 
μmol/L (range 103-348). Histological scores of graft biopsies obtained at transplantation 
and during the first month after transplantation did not predict graft outcome. 
Figure 5. Graft outcome measured by serum creatinine after 1 year and at long term. Patients were 
categorized according to Global Kidney Score (GKS Banff) in graft biopsies obtained at transplantation. 
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4.4 Paper IV 
In this paper we compared the survival of elderly kidney transplant recipients with similar 
aged patients who were accepted for transplantation but remained on dialysis. All patients 
older than 70 years who started dialysis between 1990 and 2005 and were waitlisted for 
kidney transplantation were included in the study. The patients were categorised according 
to the year dialysis was started (1990-1999 versus 2000-2005). Survival rates of 286 dialysis 
patients were analysed using a Kaplan-Meier model and a time-dependent Cox model. 
Comparisons were made between patients receiving a transplant and those who did not. In 
addition, the two time periods were compared. In the models, patients were censored from 
the waitlist group at the time of transplantation. The results were adjusted for age, sex, 
primary kidney disease, type of centre where dialysis was initiated (university vs. non 
university hospital), time on dialysis before waitlisting and dialysis modality. Patients 
starting dialysis between 1990 and 1999 had no significant long-term benefit of 
transplantation (HR for death 1.01 [0.58 – 1.75]). In contrast there was a substantial long-
term benefit of transplantation among patients starting dialysis after 2000 (HR for death 
0.40 [0.19 – 0.83], P = 0.014). Although transplant recipients had an increased risk of death 
during the first year after transplantation, they had a long-term cumulative survival benefit 
compared to those remaining on dialysis. The median survival after transplantation 
increased from 3.7 (3.0 – 4.4) years in the 1990 – 1999 cohort, to > 6.7 years in 2000 – 2007 
cohort. For those who did not receive a kidney transplant, the median survival after time of 
waitlisting did not change between the two periods; 3.4 (3.3 – 3.7) years versus 3.1 (1.8 – 
4.4) years. 
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5. DISCUSSION 
5.1 Importance of results 
5.1.1 Paper I 
This paper describes the outcomes of elderly kidney transplant recipients at our centre, 
compared with slightly younger recipients. The survival rates are compared with those 
described previously in the literature. As expected, the survival of elderly recipients is 
inferior to that of younger ones. The inferior graft survival reflects a natural higher risk of 
death with a functioning graft in the elderly. We concluded  that the five year patient 
survival of elderly recipients is acceptable and seems to be better than the survival of age-
matched patients on dialysis for whom it is previously described five year patient survival 
up to 30-35 % (24;90). However, we did not directly compare the survival between 
transplant recipients and waitlisted patients remaining on dialysis. Since transplant 
recipients constitute a selected group of patients with less comorbidity than the average age-
matched dialysis population, it is not possible to use the results of this study to draw the 
conclusion that, in elderly patients with ESRD, the prognosis is better after transplantation 
compared to continuing on dialysis. To investigate this issue further it was necessary to 
perform a study directly comparing two groups with relatively similar degree of 
comorbidity. The study was therefore important for launching the subsequent studies, 
especially the study presented in paper IV. 
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5.1.2 Paper II  
The aim of the second paper was to define modifiable clinical parameters relevant to 
survival after kidney transplantation in elderly recipients. The presence of an acute rejection 
episode was identified as a variable strongly associated with poor survival. This indicates 
that it is very important, especially in elderly recipients, to establish an immunosuppressive 
protocol that prevents rejections. Interestingly, in the senior and control groups acute 
rejection was only associated with an increased risk of graft loss, not patient death. A 
possible explanation might be that whereas younger recipients lose their grafts in rejection, 
the elderly lose their lives because of complications to the rejection treatment.   We also 
defined variables associated with the development of acute rejection episodes and these did 
not differ between the age groups. In addition, in the elderly group, time on dialysis and 
advanced donor age were also found to be modifiable variables significantly associated with 
patient survival. Somewhat surprising, the CCI score did not provide any prognostic 
information for the elderly, in contrast to the effect of the CCI score observed in the two 
younger age groups. Our interpretation is that the present screening algorithm used at our 
centre for selecting patients for transplantation worked sufficiently and in addition, in 
elderly recipients, age by itself is more important than presence of comorbid conditions. The 
fact that the median CCI score was only 3 in the elderly group supports the view that 
patients with serious comorbidity had been effectively disqualified from transplantation. 
Analyses of comorbidity in European patients requiring RRT indicate that even though 
comorbidity is an important predictor for mortality, the influence of comorbidity may be 
less important than expected when adjusted for confounders such as age, gender, primary 
renal disease, treatment modality and country (91). Reducing time on dialysis before 
transplantation to a minimum and avoidance of acute rejections should, therefore, be 
important aims of the treatment in the elderly ESRD population. An old-for-old allocation 
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strategy may be an effective way to reduce waiting time for aged recipients (76;92-95). 
However, the risk of using donors of advanced age for transplantation must be weighed 
against the alternative i.e. permanent dialysis. With increasing waiting lists and a lack of 
organs, this may be a risk worth taking in order to provide kidney transplants to elderly 
patients. 
 
5.1.3 Paper III  
Even if kidney transplantation is established as the treatment of choice for a relatively large 
number of selected elderly patients with ESRD, it may not be feasible owing to organ 
shortages and priority given to younger recipients. With long waiting times, many elderly 
patients will die or become unsuitable for transplantation before they are offered a transplant 
(96). Given the present situation with a scarcity of organs worldwide, it is necessary to 
increase the organ pool if transplantation is to be implemented as a realistic alternative for 
elderly patients. We suggest that a way of increasing the donor pool is to use organs from 
elderly deceased donors, that otherwise would not have been made available, to elderly 
recipients. It has been suggested that pre transplant histology score of the donor kidney 
might help predict outcome and long term graft function in organs from ECD (97). These 
“scoring systems” have not been sufficiently evaluated. Thus it is possible that current 
practice with selection of donor kidneys for transplantation based on donor age and pre-
transplant histopathology leads to a reduced number of available kidneys for transplantation. 
We concluded that donor age and histopathology alone could not supply us with enough 
information to determine if a kidney should be used for transplantation or not. However, it is 
important to realize the limitations of the analyses. The study is based on results from a 
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single centre, it is retrospective and the numbers of ECD transplants are low. Therefore, the 
results should be interpreted with caution.  
 
5.1.4 Paper IV  
In the fourth paper, we directly compared the outcome of kidney transplantation with the 
outcome of continuing dialysis in patients older than 70 years accepted for transplantation. 
The most important findings were 1) transplant patient survival over the last decade is 
superior to dialysis patient survival, and 2) the outcome of transplantation has improved 
markedly with the intensification of immunosuppressive protocols. There was actually no 
survival benefit of transplantation in patients included before year 2000. We believe that the 
most important reason for the improvement of outcome is the change of immunosuppressive 
protocol that was performed in 2000, as there apart from differences in immunosuppression, 
virtually were no major baseline differences between the patients of the two time eras. As 
shown in previous studies (12;38), although transplant recipients have an increased risk of 
death during the first year after transplantation, there is a significant survival benefit 
beginning after 2.5 years. In other words, in a selected population of elderly patients with 
ESRD, kidney transplantation may be the treatment of choice. This supports the statement 
made by Knoll in a recent review: “Until further evidence emerges, nephrologists should 
continue to view all of their older patients with ESRD as potential transplant candidates. If 
functional status is reasonable and no obvious contraindication is present (e.g., recent 
malignancy), then transplant evaluation should proceed with screening for cardiovascular 
disease and malignancy as suggested by guidelines” (98).  
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5.2 Study Design 
A prospective randomized clinical trial is generally regarded as the optimal scientific 
approach for evidence based medicine (99). However, performing RCTs to compare the 
outcomes of dialysis and transplantation would not be considered ethical owing to the 
superior quality of life associated with transplantation compared with dialysis. As a 
consequence, the present studies were given a retrospective, observational design. Using 
this approach, it is possible to generate and test a hypothesis by identifying significant 
associations between several factors and outcomes.  The potential of an observational study 
to make causal inferences is however less compared to an RCT (100;101). With a 
retrospective design, it is important that the groups compared are as equal as possible. In the 
evaluation of the survival benefit of transplantation versus dialysis (paper IV), the 
differences in baseline characteristics between the waitlist and the transplant groups were 
small. Therefore we regard the results as representative and reliable, despite the limitations 
of the retrospective study design. Obviously, when comparing the outcome in different 
patient groups, it is also important that the groups are comparable with respect to important 
outcome parameters. For example, in paper I, it is not surprising that survival in patients 
aged 60 – 69 years is better than in patients aged greater than 70, knowing that age is one of 
the most important risk factors for death. 
When comparing patients receiving a kidney transplant with those continuing on dialysis, it 
is extremely important to be aware of the basis used for selecting patients for 
transplantation. Just comparing the survival of kidney transplant recipients with patients on 
dialysis would be incorrect, since the patients with least comorbidity are selected for 
transplantation. In order to make the groups comparable, it was necessary to choose a 
criterion describing the patients’ eligibility, namely being accepted for the transplant 
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waitlist. In paper II, it was important that all patients in the analysis were rigorously 
screened and treated for comorbidities before they were accepted for transplantation. In 
other words, our finding does not imply that comorbidity is not associated with the 
outcomes of kidney transplantation in elderly recipients. It only informs us that, in this age 
group, with the current established medical criteria for waitlisting, evaluation of 
comorbidity at transplantation does not help us predict patient outcome.  
The precision of a study can be threatened by random errors. Random errors leads to 
increased variation of the data, but do not necessary interfere with the validity. On the other 
hand, systematic errors may bias the data in a way that threatens the validity of the study. 
Consequently, systematic errors are far more serious than random errors. 
 
5.2.1 Internal validity 
In the retrospective setting it is essential that the data collected are robust and reliable. If 
not, conclusions are drawn from unreliable sources (‘garbage in – garbage out’). The 
internal validity of a study is the representativeness of results for the particular population 
being studied. A study can be biased due to selection of patients to the study (selection 
bias), due to the measurement of the variables (information bias) or because of missing or 
incomplete control for confounders.  
Selection bias 
Selection bias are distortions that result from the procedures used to select subjects and from 
factors that influence participation (87). By having only one transplant centre serving the 
whole country and well established routines for reporting data to the registry, the input of 
data has been very satisfactory. In addition, the data collected in the Norwegian Renal 
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Registry have been rigorously controlled by the leader of the registry since its 
establishment, and virtually all patients starting RRT in Norway are included. As a 
consequence, the data of the Norwegian Renal Registry are probably among the most robust 
renal registry data world-wide, and the risk of selection bias in the registry data should 
therefore be almost negligible. However, it is also important that the extraction of data is 
performed correctly. By a mistake, 53 ‘elderly’, 64 ‘senior’ and 51 ‘control’ recipients 
transplanted between 1990 and 2005 were missed in the data extraction performed for paper 
I. The mistake was detected when an updated data set extraction for paper II was performed. 
However, a new survival analysis on the overall material revealed essentially the same 
results as originally published.  
Information bias 
Bias in evaluating an effect can occur from errors in obtaining the information. In addition 
to registry data, we also used data from hospital records to describe comorbidities, details of 
immunosuppressive treatment, and complications. Obviously, these data are more prone to 
individual variation, both by the surgeon/nephrologist responsible for registering data for 
the individual patient, and by the researcher extracting the data from the records. The 
variation caused by clinical data registration would mainly cause random errors influencing 
the precision of the estimates and not the validity. In order to make data extraction as 
consistent as possible, the process was performed by only one person. It is possible that this 
procedure may introduce a systematic information bias, for example because of 
misclassification of conditions giving score in the CCI. However, the finding that CCI score 
showed prognostic impact on the younger age groups, as expected from former analysis, 
supports the validity of our calculated indexes. The results could possibly have been even 
more robust if two researchers had performed the data extraction individually, compared 
results, and then reached consensus. The review of almost 1500 hospital records would 
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however be very time consuming, and we therefore decided to restrict this review procedure 
to one person. 
Confounding 
Confounding occurs when an investigator tries to determine the effect of an exposure on the 
outcome, but actually measures the effect of another factor, a confounding variable. A 
potential confounding variable has the following properties (102):  
1. The variable must have an association with the disease i.e. it should be a risk factor 
for the disease 
2. It must be associated with the exposure, which means that it must be unequally 
distributed between the exposed and the non-exposed groups 
3. It must not be an effect of the exposure, nor be a factor in the causal pathway of the 
disease 
 
Figure 6. Properties of a confounder (102). 
Reprinted with permission from the Nature Publishing Group and the author. 
 
There are different ways to address confounding during study design including 
randomisation, restriction or matching. Confounding may also be controlled by adjustments 
after completion of the study by using stratification or multivariate analysis. In paper IV, the 
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groups being compared are restricted as they have acceptance for transplantation as a 
criterion for inclusion. In addition, the background characteristics reveal only minor 
differences between those patients who were transplanted and those who were not. This may 
indicate that confounding was no major problem in the analysis. When adjusting for 
potential confounders it is essential to know the value of the suspected variable. For 
instance, smoking is known to be a risk factor for cardiac death and is therefore a potential 
confounder in the survival analyses. Unfortunately, reliable information about smoking was 
not available in our data set and by this; we were not available to control our analyses for 
smoking habits.  
 
5.2.2 External validity 
External validity or generalization describes the relevance of the study to a specified patient 
population. Although RRT is conducted at several nephrology units throughout the country, 
the transplant activity is centralized at Rikshospitalet. The study, therefore, uses data from a 
single transplant centre, which may be regarded as a limitation. It could be claimed that the 
study describes the results of a national transplant policy that is not applicable to other 
countries. However, the fact that all patients have been treated at the same transplant centre, 
following the same acceptance criteria, and the same standard immunosuppressive protocol, 
makes these data robust and may also bring additional strength to the study. Furthermore, 
the robust and complete national Norwegian registry of RRT patients has made it possible to 
perform the study with almost no patients being lost to follow up. 
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5.3 Methods 
5.3.1 Kaplan-Meier method 
The Kaplan-Meier method has already been described in detail. Even though the results are 
estimates of survival and not actual survival figures, the Kaplan-Meier method is generally 
accepted as the best way to describe survival. If a high percentage of patients included in the 
analysis reach an event, as was the case in our studies, the result becomes more 
representative of actual survival. Comparing survival between groups of patients by the log 
rank test is also well established in the literature (83-85). However, when the survival 
curves cross each other due to a change of risk in one of the groups, the log rank test is no 
longer applicable. In this situation it is necessary to introduce a time dependant variable as 
we did in paper IV. 
 
5.3.2 Cox regression 
The Cox proportional hazard regression method is widely accepted as a tool for identifying 
variables which impact on the outcome in survival studies. It is important to select the 
variables tested in the model based on best clinical knowledge. By introducing several 
variables and combining them in a multivariate model, it is possible to adjust the variables 
for each other and thereby get closer to the real independent impact of each factor. The 
number of variables included in the model should, as a rule, not exceed 10 % or the square 
root of the number of events (86). If there are a large number of potential explanatory 
variables, the variables eventually included in the multivariate model may first be tested in a 
univariate analysis. Only those variables having significant or near significant influence in 
the univariate analysis should then be implemented into the multivariate model. In our 
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analysis of variables associated with patient death in paper II, there were 237 events in the 
elderly group, and after univariate testing, we eventually implemented 13 variables into the 
multivariate model. When selecting variables, it is also important to be aware of the effect 
of, and adjust for, confounding factors. In addition, during the interpretation of the results, it 
is important to be aware that there may exist unknown or unmeasured confounders not 
implemented in the model. 
 
5.4 Ethical considerations 
In the context of organ shortage, transplantation of elderly patients may become an ethical 
issue. Even if we have justified that kidney transplantation, when successful, improves both 
the survival and the quality of life for selected elderly patients with ESRD, an ethical 
dilemma arises when a kidney is allocated to an elderly person implicating that a young 
person on the waiting list has to wait longer for an appropriate organ. On the other hand, 
elderly patients are more likely to die on the waiting list, and it is therefore important to 
reduce the waiting time as much as possible.  It is possible to increase the organ pool by 
increased use of ECDs as we have described in paper III. An old-for-old policy like this 
could make it possible to allocate ECD kidneys to elderly recipients on the deceased donor 
waiting list, and thereby reduce their time on dialysis. This can be implemented without 
simultaneously increasing the waiting time for younger patients on the list. Giving organs of 
potential “lower-quality” to elderly recipients, raises further both moral and ethical 
considerations. The policy of using ECD to older recipients has, however, already been 
adopted with success in several countries, and elderly transplant candidates are among those 
who are most likely to receive optimal benefit from ECD kidneys (103).  
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6. CONCLUSIONS AND IMPLICATIONS 
6.1 Paper I 
We found no difference in graft survival between elderly, senior and control patients when 
censored for death with a functioning graft. As expected, the elderly and senior recipients 
had inferior survival, compared with the control group. Given the poor prognosis of these 
patients in dialysis we consider a 5-year patient survival rate of 56% in patients over 70 
years of age to be acceptable. Elderly patients with ESRD should be considered for 
transplantation, and a selected group should be offered the option. 
 
6.2 Paper II 
Long time on dialysis was associated with reduced survival in kidney transplant recipients 
over 70 years of age. Low acute rejection rates improved outcomes for elderly kidney 
recipients. CCI score at transplantation did not provide a benefit in the selection of elderly 
patients for kidney transplantation, although it is known to be useful in younger patients. To 
obtain the best results, treatment of elderly recipients should aim at reducing time on 
dialysis before transplantation and avoid acute rejection episodes.  
 
6.3 Paper III 
Kidneys from deceased donors over 75 years perform acceptably as single transplants and 
should be considered for use in elderly recipients. Two selected histological graft score 
systems gave no supplementary information on the long-term outcome of the graft. 
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6.4 Paper IV 
Elderly patients ( 70 years old) on dialysis treatment, who fulfil the established medical 
criteria for transplantation, have improved survival following kidney transplantation, 
compared with patients accepted for transplantation but continuing dialysis. There has been 
a substantial improvement in long-term survival over the last decade, partly due to a more 
potent immunosuppressive protocol. Given a sufficient supply of organs, transplantation 
may be the preferred treatment for selected elderly patients with ESRD.  
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6.5 Answers to the research questions 
Our initial key questions may be answered as follows: 
1. Kidney transplantation is safe for selected elderly ESRD patients and should be 
the preferred treatment without an upper age limit. 
2. Time on dialysis prior to transplantation and frequency of acute rejection 
episodes are modifiable clinical variables relevant to improve kidney 
transplantation outcomes in the elderly. 
3. Kidneys from old deceased donors should not be discarded just because of 
advanced age. 
4. Kidney transplantation is superior to dialysis in elderly patients with ESRD 
fulfilling the established criteria for acceptance onto a kidney transplant 
waiting list. 
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7. FUTURE RESEARCH 
7.1 Health economic analyses 
Our project was not designed as a health economic study. We have, therefore, not evaluated 
the economic aspects of transplantation versus continuing dialysis in our elderly study 
population. Previous studies have revealed that kidney transplantation is the most cost-
effective and preferred mode of RRT (33;104). In a paper from Sweden, the annual cost of 
RRT is estimated to be $70,796 for a patient on haemodialysis, and $46,018 for a patient on 
peritoneal dialysis. Kidney transplantation is estimated to cost $70,000 during the first year, 
and $14,159 per year thereafter with a functioning transplant (105). Obviously, the exact 
costs will vary between countries depending on the organisation and financing of medical 
care in each country. The costs may also vary according to the age of the patients. A health 
economic study comparing the costs related to various types of RRT will, therefore, provide 
important information to help determine future priorities for RRT. 
 
7.2 Prospective evaluation of comorbidity 
It may not be possible to perform an RCT comparing the outcomes of kidney transplantation 
with dialysis. However, it may be possible to investigate the impact of comorbidity in a 
prospective manner.  If comorbidity data (CCI) was reported systematically to the registry at 
the start of RRT and at the time of transplantation, the effect of comorbidity could be 
studied prospectively, not only in the elderly, but in all age groups. 
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7.3 Immunosuppression 
In paper II we found an association between acute rejection episodes and poor survival in 
elderly kidney transplant recipients. In paper IV we found that there were significant 
improvements in survival after the introduction of newer and more potent 
immunosuppressive protocols. In the retrospective setting, however, we cannot provide 
evidence for the causal inference between the level of immunosuppression and the outcome. 
It has been proposed that MMF is perhaps less safe than AZA in the elderly (106), but our 
study has shown that survival has improved over the last decade following the introduction 
of MMF. Furthermore it is debated whether other strategies as for example induction 
therapy with thymoglobulin/IL-2R antagonist agents or delayed introduction/avoidance of 
calcineurin inhibitors, may be beneficial in a setting with elderly donors and recipients (107-
110). There is definitely a need for further prospective studies evaluating optimal 
immunosuppression strategies in elderly recipients (111). 
 
7.4. Graft preservation 
It is possible, and likely, that grafts from ECDs may benefit from improved methods of graft 
preservation including artificial extra-corporeal circulation of the graft (112) and new 
perfusion solutions. In addition, the ideal balance between short ischaemia time and good 
immunological match has yet to be established. 
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